Novo Nordisk A/S (NYSE:NVO) Position Raised by EagleClaw Capital Managment LLC

EagleClaw Capital Managment LLC increased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 4.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 65,850 shares of the company’s stock after purchasing an additional 2,575 shares during the period. Novo Nordisk A/S accounts for about 1.3% of EagleClaw Capital Managment LLC’s investment portfolio, making the stock its 26th largest holding. EagleClaw Capital Managment LLC’s holdings in Novo Nordisk A/S were worth $7,841,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of NVO. Natixis increased its holdings in shares of Novo Nordisk A/S by 748.1% in the first quarter. Natixis now owns 5,903 shares of the company’s stock valued at $758,000 after buying an additional 5,207 shares in the last quarter. Crewe Advisors LLC purchased a new position in Novo Nordisk A/S during the 1st quarter worth approximately $50,000. Vident Advisory LLC grew its position in Novo Nordisk A/S by 4.2% during the 1st quarter. Vident Advisory LLC now owns 31,522 shares of the company’s stock worth $4,048,000 after purchasing an additional 1,258 shares in the last quarter. CreativeOne Wealth LLC grew its position in Novo Nordisk A/S by 223.6% during the 1st quarter. CreativeOne Wealth LLC now owns 17,558 shares of the company’s stock worth $2,254,000 after purchasing an additional 12,132 shares in the last quarter. Finally, Wellington Wealth Strategies LLC. purchased a new position in Novo Nordisk A/S during the 1st quarter worth approximately $2,294,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 0.7 %

NVO traded up $0.76 during mid-day trading on Wednesday, hitting $103.39. The stock had a trading volume of 471,032 shares, compared to its average volume of 4,464,422. The stock’s fifty day simple moving average is $117.40 and its 200-day simple moving average is $129.27. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The firm has a market capitalization of $463.97 billion, a price-to-earnings ratio of 33.22, a price-to-earnings-growth ratio of 1.31 and a beta of 0.42. Novo Nordisk A/S has a 1-year low of $94.73 and a 1-year high of $148.15.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. BMO Capital Markets lowered their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.